Comparison of biochemical recurrence in prostate cancer patients treated with radical prostatectomy or radiotherapy.
10.4111/kju.2015.56.10.703
- Author:
Dong Soo KIM
1
;
Seung Hyun JEON
;
Sung Goo CHANG
;
Sang Hyub LEE
Author Information
1. Department of Urology, Kyung Hee University School of Medicine, Seoul, Korea. hyubv@naver.com
- Publication Type:Comparative Study ; Original Article
- Keywords:
Prostatic neoplasms;
Prostatectomy;
Radiotherapy;
Recurrence
- MeSH:
Aged;
Humans;
Kaplan-Meier Estimate;
Male;
Middle Aged;
Neoplasm Grading;
Neoplasm Recurrence, Local;
Neoplasm Staging;
Prostate-Specific Antigen/blood;
Prostatectomy/*methods;
Prostatic Neoplasms/blood/pathology/*radiotherapy/*surgery;
Retrospective Studies
- From:Korean Journal of Urology
2015;56(10):703-709
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: We evaluated the biochemical recurrence (BCR) of prostate cancer patients treated by radical prostatectomy (RP) or radiotherapy (RT). MATERIALS AND METHODS: Patients who underwent RP or RT as primary definitive treatment from 2007 were enrolled for this study. They were divided into two groups; the low-intermediate risk group and the high risk group according to the National Comprehensive Cancer Network guidelines. We compared differences such as age, prostate specific antigen, Gleason score, follow-up duration, clinical T staging, and BCR. Their BCR-free survival rates were analyzed. RESULTS: A total of 165 patients were enrolled. There were 115 patients in the low-intermediate risk. Among them, 88 received RP and 27 underwent RT. BCR occurred in 9 of the RP patients (10.2%) and 3 of the RT patients (11.1%). For the high risk group, 50 patients were included. RP was performed in 25 patients and RT in 25 patients. BCR was observed in 4 of the RP patients (16%) and 12 of the RT patients (48%). There were no differences in BCR-free survival for the low-intermediate group (p=0.765). For the high risk group, the RP group had a higher BCR free survival rate (p=0.032). CONCLUSIONS: No difference of BCR and BCR-free survival was seen in the low-intermediate risk group but lower BCR and better BCR-free survival were observed for patients that received RP in the high risk group. RP should be a more strongly considered option when deciding the treatment method for selected high risk patients.
